Friday, September 30, 2022


Biotechnology News Magazine

Dr Zachariah P Zachariah: New Addition to the Boditech Advisory Board

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Dr Zachariah P Zachariah  is the first member of the newly formed U.S. based advisory board.

The board will support the publicly traded company’s expansion into the U.S. and Canada, beginning with a new manufacturing site in Miami, Florida. Boditech plans to hire hundreds of Americans to help bring faster, lower-cost diagnostic testing to North America.

Boditech tests cover many critical areas of medicine, from cardiac health to cancer. The company also produces COVID-19 antibodies and over-the-counter rapid antigen tests.

“In the U.S., it can take up to three days to get diagnostic test results — an unacceptable wait that leaves patients in limbo as costs mount,” said Eui-Yul Choi, PhD, Boditech’s co-founder and CEO. “The COVID pandemic has brought this problem into perspective for millions of Americans, but delayed test results plague many branches of medicine. Boditech’s point-of-care tests deliver results in 12 to 15 minutes. We are excited to be bringing this technology to North America with support from Dr. Zachariah, one of the world’s finest cardiologists and a proven leader with connections across Florida and around the globe.”

Dr. Zachariah is a clinical faculty member of the University of Miami and Medical Director of UHealth Cardiology, Fort Lauderdale. He has performed more than 30,000 heart catheterizations and interventional procedures in Broward County and participated in numerous clinical trials.

A longtime member and former chair of the Florida Board of Medicine, Dr. Zachariah also serves on the National Heart, Lung, and Blood Institute of the National Institutes of Health and several other boards. He has spent decades lending his expertise to organizations around the world, including serving in the 1990s on the U.S. delegation to the World Health Organization in Geneva, Switzerland. Three governors have declared five days in his honor, observed throughout Florida.

“For clinicians and patients, timely information is paramount,” said Dr. Zachariah. “I believe Boditech testing is poised to be a game-changer, and I’m eager to get to work assisting that mission.”

Founded in South Korea in 1998, Boditech Med markets and sells more than 90 biomarker products in 120 countries.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine